Immunocine Cancer Center

What Immunocine Cancer Center does

Immunocine Cancer Center is a privately held, Mexico-based specialty biotech and treatment provider founded in 2011 by Matthew Halpert, PhD, focused exclusively on personalized dendritic cell immunotherapy for cancer patients. The company operates two clinical sites — in Cancun (primary, cGMP-aligned and ISO-7 certified) and San José del Cabo (secondary, opened 2023) — and is legally governed under Texas law despite its Mexican operating footprint. It treats international patients, primarily US residents, who travel to Mexico for a 6-week protocol that is otherwise awaiting US FDA clinical trial completion.

The core product is the Immunocine Dendritic Cell Treatment (IDCT), a proprietary "first-in-class" personalized immunotherapy built on a patented Double Loaded dendritic cell technology. Patient dendritic cells are loaded simultaneously with tumor-derived mRNA (engaging the MHC Class I pathway) and cancer-associated antigens/proteins (MHC Class II pathway), driving a comprehensive Th1-polarized immune response that activates CD8+ T cells and Natural Killer cells and produces long-lived CD8+CD161+ memory T cells. Treatment is accompanied by structured immune monitoring via flow cytometry, circulating tumor cell gene analysis, cytokine panels, and antigen recall testing. The company accepts roughly 15% of applicants, indicating stringent eligibility screening.

Commercial operations run on a high-touch, patient-pay economics model with minimal insurer intermediation. The full treatment program is priced at $120,000 USD as a one-time fee inclusive of medical, scientific, and concierge components (excluding airfare/lodging); ancillary revenue comes from $9,000 dendritic cell boosters, $6,000 tissue preservation (Immunocine Preserve), and $395 infectious disease testing through partner Ulta Lab Tests. Patient financing is enabled via LightStream and Life Credit partnerships, with a contingency-based third-party reimbursement service for post-treatment insurance claims. Care is delivered directly at company facilities, supported by a multidisciplinary team led by a CEO-founder PhD immunologist, an MD chief oncologist, an interventional radiology chief, and notably a former Johns Hopkins oncologist-immunologist advisor. The company is governed independently with no disclosed institutional capital, positioning it as a founder-controlled specialty treatment operation rather than a venture-backed biotech.

Name

Immunocine Cancer Center

Legal name

Immunocine Cancer Center

Website

https://immunocine.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Immunocine Cancer Center delivers personalized double-loaded dendritic cell immunotherapy (IDCT) to late-stage solid tumor patients, primarily US travelers treated at its Cancun and San José del Cabo, Mexico facilities for a $120,000 per-patient fee.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Other Ambulatory Health Care Services (6219), Medical and Diagnostic Laboratories (6215)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Dendritic Cell & Other APC-based Therapies (HLAAABAF)

akta.pro secondary industries

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Dendritic cell immunotherapy
• Personalized cancer treatment
• Cell therapy services
• Cancer immunotherapy clinic
• Medical tourism oncology

Headquarters

HQ city

Cancún

HQ country

Mexico

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Core Treatment Program: One-time fee model covering all core medical, scientific, and logistical components of personalized Dendritic Cell therapy including doctors, specialists, lab work, scans, procedures, collection and manufacturing of personalized therapy, image-guided administration, storage of extra dendritic cells for potential boosts, immune-enhancing agents, continual medical team interaction, concierge coordination, and patient-specific immunological analytics.
2. Dendritic Cell Boosters: Future Dendritic Cell 'boost' treatments available for $9,000 per boost if pursued later for continued immune support.
3. Tissue Preservation Services: Tumor tissue preservation kit and service for $6,000 (non-refundable, partially credited toward future treatment) to preserve biopsied or resected tissue for potential future use.
4. Infectious Disease Testing: Facilitated infectious disease testing through partner Ulta Lab tests for $395 if patient needs assistance with required biosafety testing.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Immunocine delivers a first-in-class personalized dendritic cell immunotherapy (IDCT) using proprietary Double Loaded dendritic cell technology that trains the patient's own immune system to detect and destroy cancer cells. The treatment program consists of three dendritic cell administrations spaced two weeks apart, delivered at cGMP-aligned, ISO-7 certified facilities in Cancun and San José del Cabo, Mexico, and is bundled with concierge coordination, immune monitoring, and post-treatment support at a $120,000 USD program fee.

Product overview

Immunocine Cancer Center offers a single unified product: the Immunocine Dendritic Cell Treatment (IDCT), a first-in-class personalized immunotherapy that utilizes proprietary Double Loaded dendritic cell technology. The treatment program is structured in three phases: Pre-Treatment Preparation (Phase 01), the core IDCT administration consisting of three dendritic cell treatment sessions spaced two weeks apart (Phase 02), and Post-Treatment Support including ongoing monitoring and optional booster treatments (Phase 03). Additional services include complimentary medical evaluation, tissue preservation (Immunocine Preserve), comprehensive immune response monitoring, and CARE team ongoing support. The treatment program fee is $120,000 USD, with optional dendritic cell boosters at $9,000 each.

Differentiator

Problem solved

Functional benefit

Products and services

• Immunocine Dendritic Cell Treatment (IDCT) A first-in-class personalized immunotherapy utilizing proprietary Double Loaded dendritic cell technology to train a patient's immune system to detect and fight cancer cells throughout the body. Delivered as three dendritic cell administration sessions two weeks apart at facilities in Cancun, Mexico, priced at $120,000 USD as an all-inclusive program.
• Dendritic Cell Booster Stored dendritic cells administered as booster treatments after the initial IDCT program if the medical team determines additional immune support is beneficial, priced at $9,000 per booster.
• Immunocine Preserve (Tissue Preservation) Service to properly preserve biopsied or resected tumor tissue (minimum 250 mg) using RNAlater or flash-freezing methods for potential future use in treatment, priced at $6,000 (non-refundable, partially credited toward future treatment).
• Medical Evaluation Services Complimentary preliminary and final medical evaluations including questionnaire, medical records review, and consultations with oncologists, radiologists, and hematologists to determine treatment eligibility.
• Infectious Disease Testing Facilitation Facilitated infectious disease testing (HIV, Hepatitis B/C, and other biosafety tests) through partner Ulta Lab Tests, required for treatment in the ISO-7 certified laboratory; priced at $395 if patient needs assistance with testing.
• CARE Team Support Ongoing remote support from integrative oncologists, metabolic advisors, and nurse navigators after patients return home, including data review and booster planning.

Quantifiable outcome

• Patients observed cancer-free for extended periods including cases exceeding 7 years, with several approaching 5 years with no recurrence
• +1 more outcomes

Named customers12 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• Amerimed HospitalscoreStrategic or Co-development PartnerAmerimed is an internationally accredited private hospital network in Cancun where Immunocine administers treatments. Provides fully equipped medical facilities including emergency capabilities for patient safety during and after treatment procedures.
• Ulta Lab TestssupportingStrategic or Co-development PartnerPartnered laboratory service providing required infectious disease testing (HIV, Hepatitis B/C, and other conditions) for patients. Testing costs $395 if facilitated through Immunocine for biosafety compliance in their ISO-7 certified laboratory.
• LightStream Medical FinancingsupportingOthersThird-party provider offering fixed-rate medical loans with terms of 3-7 years and no collateral required. Fast approval process, often within 5 days. Helps patients finance the $120,000 treatment cost.
• Life CreditsupportingOthersThird-party medical financing provider that may allow patients to borrow against their life insurance policy to cover treatment costs.
• Third-Party Reimbursement GroupsupportingGTM or Marketing PartnerPartnered reimbursement assistance service specializing in medical tourism. Works on contingency basis (no upfront cost) to help patients submit documentation for insurance reimbursement claims after treatment. Only takes fee from recovered funds.
• Heal NavigatorsupportingChannel Partner/ Reseller/ DistributorGlobal platform helping cancer patients explore and access vetted integrative and alternative treatments. Co-founder Adi Hertz born from personal experience. Immunocine CEO Dr. Matt Halpert appeared on Heal Navigator podcast to discuss IDCT.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Others

• Cryoport: Provider of temperature-controlled logistics for cell and gene therapies, including cryogenic shipping of autologous cell products. Relevant adjacent/ecosystem participant given Immunocine's reliance on cold-chain handling of personalized dendritic cell products.
• Heal Navigator: Global platform that helps cancer patients explore vetted integrative and alternative treatments, including referring patients to Immunocine. Comparable as a channel partner in the cancer medical tourism patient acquisition ecosystem.

Direct peers

• CHIPSA Hospital: Tijuana-based hospital offering alternative and integrative cancer treatments to international patients, including some immunotherapy protocols. Comparable as a Mexico-based cancer treatment provider competing for the same US medical tourism market segment.
• Hope4Cancer Treatment Centers: Mexico-based (Tijuana/Cancun) alternative cancer treatment center targeting US medical tourism patients with non-conventional therapies. Directly comparable as a competitor for US cancer patients willing to travel to Mexico, sharing the same regulatory environment and patient acquisition channels.
• Northwest Biotherapeutics: Developer of DCVax, an autologous dendritic cell vaccine platform for solid tumors including glioblastoma. Directly comparable as a personalized dendritic cell therapy company targeting similar cancer indications, though pursuing FDA pathways rather than international compassionate-use.
• Sotio: Czech-based clinical-stage biotech developing autologous dendritic cell vaccines (e.g., SO-C101, DCVAC) for prostate, lung, and ovarian cancer. Comparable as a developer of personalized DC-based cancer immunotherapies targeting similar solid tumor indications.
• Dendreon (Sanpower Group): Created Provenge (sipuleucel-T), the first FDA-approved autologous dendritic cell therapy for prostate cancer. Closest historical comparable for IDCT as a personalized DC therapy commercial entity, providing precedent on both market opportunity and operational challenges of cell therapy commercialization.

Broad incumbents

• Iovance Biotherapeutics: US-based commercial-stage developer of tumor-infiltrating lymphocyte (TIL) therapies, including lifileucel for advanced melanoma. Comparable as a personalized cell therapy company targeting late-stage solid tumors where conventional treatment has failed — though using TILs rather than dendritic cells.
• Cancer Treatment Centers of America (City of Hope): Network of US-based specialty oncology hospitals (now part of City of Hope) offering comprehensive cancer treatment including immunotherapy. Comparable as a specialty outpatient cancer care provider, though operating within the US mainstream insurance system.
• Adaptimmune: Clinical-stage biotech developing engineered TCR-T cell therapies for solid tumors (e.g., Tecelra for synovial sarcoma). Adjacent peer in the personalized cell therapy oncology space pursuing FDA approval pathways.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xfacebook.com/Immunocine
• YouTubeyoutube.com/@immunocinecancercenter
• Facebookfacebook.com/Immunocine
• LinkedInlinkedin.com/company/immunocine
• Instagraminstagram.com/immunocine

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immunocine Cancer Center